Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.36 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8455901 | 0.89 | BRD4 (0.37) | ALDH1A1TSHRHPGDPOLBMEN1 | |
| SCHEMBL8449363 | 0.88 | KIF11 (0.49) | ALDH1A1TSHRHPGDPOLBMEN1 | |
| SCHEMBL36740 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TSHRHPGDPOLBAOX1 | |
| SCHEMBL30360260 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TSHRHPGDPOLBAOX1 | |
| SCHEMBL28422136 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TSHRHPGDPOLBMEN1 | |
| SCHEMBL3116390 | 0.83 | ALDH1A1 (0.43) | ALDH1A1TSHRHPGDPOLBMEN1 | |
| SCHEMBL3857336 | 0.83 | ALDH1A1 (0.43) | ALDH1A1TSHRHPGDPOLBAOX1 | |
| SCHEMBL498989 | 0.81 | ALDH1A1 (0.64) | ALDH1A1TSHRHPGDPOLBKMT2A | |
| SCHEMBL21738199 | 0.81 | ALDH1A1 (0.58) | ALDH1A1TSHRHPGDPOLBAOX1 | |
| SCHEMBL4479223 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TSHRHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-20220031661-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | UNIVERSITY OF KANSAS | 2022-02-03 | — | — | US | disclosed |
| CN-108883099-B | Thiazolidinone compounds and use thereof | 石全 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020117832-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | UNIVERSITY OF KANSAS (US) | 2020-06-11 | — | — | WO | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009004430-A1 | N-BENZYL OXAZOLIDINONES AND RELATED HETEROCYCLEIC COMPOUNDS AS POTENTIATORS OF GLUTAMATE RECEPTORS | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | ALDH1A1 295/4885TSHR 131/4885HPGD 289/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | ALDH1A1 295/4885TSHR 131/4885HPGD 289/4885 |
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | ALDH1A1 150/4885TSHR 1877/4885HPGD 137/4885 |
| US-20220031661-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | BLVRB, TFPI, ETFB | ALDH1A1 2584/4885TSHR 1599/4885HPGD 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.